Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
So what: Interestingly, the move up came despite lower full-year guidance. Management cited $5 million worth of revenue impact from the twin tsunamis that struck Japan in March in lowering Volcano's 2011 targets from a range of $347 million to $352 million in revenue and $0.22 to $0.24 in per-share earnings to $342 million to $347 million in revenue and $0.19 to $0.21 in per-share profit. The revised estimates remained within reach of the midpoint of Wall Street's own projections.
Now what: Not so for Q1 results, however. Demand for Volcano's cardiac-imaging technology surged as revenue improved by 22% to $80.9 million. Markedly higher gross margin -- up 560 basis points year over year -- transformed last year's $0.08-per-share loss into a $0.02-per-share profit. Analysts had been expecting $78.4 million and a $0.03-per-share loss. Even though Volcano trades for a significant premium to peers Boston Scientific (NYSE: BSX ) and St. Jude Medical (NYSE: STJ ) , judging by these results, it's worth every penny.
Interested in more info on Volcano? Add it to your watchlist.